CanSino's New covid-19 Vaccine is Included in the World Health Organization's Emergency Use List

On May 19, 2022, Beijing time, the World Health Organization released information on its official website, officially listing CanSino Bio’s recombinant covid-19 vaccine (type 5 adenovirus vector) on its emergency use list. The Beijing company's new crown inactivated vaccine and Kexing Zhongwei's covid-19 inactivated vaccine are the third domestic vaccines to be included in the WHO emergency use list.

The State Food and Drug Administration has maintained a good consultative relationship with the World Health Organization for a long time, and has cooperated on matters related to the supervision of the new coronavirus vaccine.

On the evening of May 19, CanSino announced that the company's recombinant new coronavirus vaccine (type 5 adenovirus vector) Keweisha was included in the "emergency use list", and the product was constructed by genetic engineering methods to replicate defective human beings Adenovirus type 5 is a vector that can express the new coronavirus S antigen and is intended to be used to prevent diseases caused by new coronavirus infection. At the same time, it does not contain preservatives, adjuvants and animal-derived components. However, even if it is included in the "emergency use list", the company still needs to conduct business negotiations with interested countries. If overseas countries increase purchases and use Keweisha in the future, it will inevitably have a certain positive impact on CanSino's performance.

Up to now, CanSino Bio’s covid-19 vaccine Kwesa has obtained emergency use authorization or conditional marketing approval granted by more than 10 countries, including China, Pakistan, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Indonesia, United Arab Emirates Emirate and Malaysia. At the same time, CanSino Bio has also cooperated with a number of countries including Mexico, Pakistan and Malaysia to establish filling production lines to achieve localized production of new crown vaccines and achieve new breakthroughs in anti-epidemic cooperation. Based on its favorable clinical trial results, CanSino Bio’s Covid-19 vaccine has been approved as a sequential booster vaccine in China, Argentina, Malaysia and Indonesia. At present, the company has established a mature business service network and an efficient and safe supply and distribution system in China, Southeast Asia, the Middle East, Latin America and other countries and regions.

As soon as the news came out, on May 20, Kangxunuo's AH shares rose sharply at the opening; as of today's close, its stock price was 164.4 yuan per share, a single-day increase of 12.14%.